A Belldegrun

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies
    Arie S Belldegrun
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:2457-63. 2008
  2. ncbi request reprint Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system
    A Belldegrun
    Department of Urology, University of California Los Angeles, Los Angeles, CA 90095 1738, USA
    J Clin Oncol 17:2868-75. 1999
  3. ncbi request reprint The role of lymphadenectomy in renal cell carcinoma
    Hyung L Kim
    Department of Urology, David Geffen School of Medicine at UCLA 66 128 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Curr Urol Rep 5:25-9. 2004
  4. ncbi request reprint Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology
    A Belldegrun
    Department of Urology, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Hum Gene Ther 12:883-92. 2001
  5. ncbi request reprint Gene and immune therapy for renal cell carcinoma
    A J Pantuck
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    Int J Urol 8:S1-4. 2001
  6. ncbi request reprint New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions
    A J Pantuck
    UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1738, USA
    Urology 57:95-9. 2001
  7. ncbi request reprint Biology of renal cell carcinoma: changing concepts in classification and staging
    A J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles 90095-1738, USA
    Semin Urol Oncol 19:72-9. 2001
  8. ncbi request reprint Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors
    L Wu
    Department of Urology, UCLA School of Medicine, Box 951738, Los Angeles, CA 09095-1738, USA
    Gene Ther 8:1416-26. 2001
  9. ncbi request reprint Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor
    C L Tso
    Department of Urology, UCLA Kidney Cancer Program, University of California Los Angeles, Los Angeles, California 90095, USA
    Cancer Res 61:7925-33. 2001
  10. ncbi request reprint Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer
    A Belldegrun
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 166:1316-21. 2001

Detail Information

Publications76

  1. doi request reprint Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies
    Arie S Belldegrun
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Cancer 113:2457-63. 2008
    ..The management of renal cell carcinoma (RCC) is evolving toward less extirpative surgery and the use of targeted therapy. The authors set out to provide a benchmark against which emerging therapies should be measured...
  2. ncbi request reprint Efficacy of nephron-sparing surgery for renal cell carcinoma: analysis based on the new 1997 tumor-node-metastasis staging system
    A Belldegrun
    Department of Urology, University of California Los Angeles, Los Angeles, CA 90095 1738, USA
    J Clin Oncol 17:2868-75. 1999
    ..To analyze the experience with nephron-sparing surgery as a treatment modality for renal cell carcinoma (RCC)...
  3. ncbi request reprint The role of lymphadenectomy in renal cell carcinoma
    Hyung L Kim
    Department of Urology, David Geffen School of Medicine at UCLA 66 128 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Curr Urol Rep 5:25-9. 2004
    ..The potential benefits for lymphadenectomy include more accurate staging, decreased risk of local recurrence, and improved survival. However, the benefits of lymph node dissection have not been proven...
  4. ncbi request reprint Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology
    A Belldegrun
    Department of Urology, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Hum Gene Ther 12:883-92. 2001
    ..This phase I trial demonstrated the safety of intraprostatic Leuvectin injection, with transient PSA-based responses seen after therapy...
  5. ncbi request reprint Gene and immune therapy for renal cell carcinoma
    A J Pantuck
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    Int J Urol 8:S1-4. 2001
    ..Current immunotherapy and gene therapy strategies, including methods of cytokine delivery and tumor-cell-based vaccines, are presented...
  6. ncbi request reprint New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions
    A J Pantuck
    UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California 90095-1738, USA
    Urology 57:95-9. 2001
    ..Current results of clinical immune/gene therapy protocols will be reviewed with consideration towards the concept of cancer prevention...
  7. ncbi request reprint Biology of renal cell carcinoma: changing concepts in classification and staging
    A J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles 90095-1738, USA
    Semin Urol Oncol 19:72-9. 2001
    ..In this review, the results of international consensus efforts to achieve uniform classification systems for RCC are outlined and some future directions are considered...
  8. ncbi request reprint Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors
    L Wu
    Department of Urology, UCLA School of Medicine, Box 951738, Los Angeles, CA 09095-1738, USA
    Gene Ther 8:1416-26. 2001
    ....
  9. ncbi request reprint Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor
    C L Tso
    Department of Urology, UCLA Kidney Cancer Program, University of California Los Angeles, Los Angeles, California 90095, USA
    Cancer Res 61:7925-33. 2001
    ..These findings may have important implications for the use of GM-CSF-G250 FP as a tumor vaccine for the treatment of patients with advanced kidney cancer...
  10. ncbi request reprint Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer
    A Belldegrun
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 166:1316-21. 2001
    ..CONCLUSIONS: Currently patients with advanced prostate carcinoma have expanded therapeutic options available in the form of molecular based phases II and III clinical trials...
  11. ncbi request reprint Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report
    L M Liau
    Division of Neurosurgery, Department of Neurology, University of California at Los Angeles School of Medicine, Los Angeles, California 90095 6901, USA
    Neurosurg Focus 9:e8. 2000
    ..Phase I trials for malignant glioma are currently underway...
  12. ncbi request reprint Use of chromosome 9p status to identify a subset of high-risk localized renal cell carcinoma
    J C LaRochelle
    University of California, Los Angeles, Santa Monica, CA University of California, Los Angeles, Los Angeles, CA
    J Clin Oncol 27:5090. 2009
    ....
  13. pmc Tumor biology and prognostic factors in renal cell carcinoma
    David S Finley
    Institute of Urologic Oncology, UCLA David Geffen School of Medicine, Los Angeles, California 90095 1738, USA
    Oncologist 16:4-13. 2011
    ..The discovery of prognostic factors and development of comprehensive nomograms to stratify patient risk and predictive biomarkers to facilitate individualized treatment selection and predict patient response to therapy also are reviewed...
  14. ncbi request reprint Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity
    P Frost
    Department of Microbiology and Immunology, UCLA School of Medicine, USA
    Cell Immunol 180:70-83. 1997
    ..Sensitization of tumor cells by drugs may augment the efficacy of immunotherapy in the eradication of tumor cells that are resistant to Fas-L-mediated killing...
  15. pmc Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis
    Y C Yang
    Department of Epidemiology, UCLA School of Public Health and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA
    Br J Cancer 95:1455-8. 2006
    ..Neither the polymorphism nor TP53 mutation status was an independent predictor of prognosis, but they might act jointly on the disease-specific survival of patients...
  16. ncbi request reprint Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    BJU Int 96:281-5. 2005
    ....
  17. ncbi request reprint Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Allan J Pantuck
    Departments of Urology and Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:693s-696s. 2007
    ..Although evidence-based medical practice suggests a role for nephrectomy before the use of targeted agents, the arguments for and against this practice will be weighed...
  18. ncbi request reprint Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication
    Jean Jacques Patard
    Department of Urology, Rennes University Hospital, Rennes, France
    Eur Urol 52:148-54. 2007
    ..To analyse through a large multicentre series, morbidity of nephron-sparing surgery (NSS) in relation to tumour size and surgical indication...
  19. ncbi request reprint Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    Semin Oncol 33:607-13. 2006
    ....
  20. ncbi request reprint Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system
    Gang Zeng
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    J Immunol 177:3582-9. 2006
    ..Calreticulin/NY-ESO-1 interactions provide a direct link between NY-ESO-1, the innate immune system, and, potentially, the adaptive immune response against NY-ESO-1...
  21. ncbi request reprint Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    J Urol 173:1853-62. 2005
    ..This review highlights such controversies and provides an update on current staging modalities, prognostic factors and targeted molecular therapy for RCC...
  22. ncbi request reprint Adjuvant treatment for renal cell carcinoma
    John S Lam
    David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Expert Opin Pharmacother 7:705-20. 2006
    ..This review will discuss the role and current status of adjuvant therapies for renal cell carcinoma...
  23. ncbi request reprint Long-term outcomes of the surgical management of renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    World J Urol 24:255-66. 2006
    ....
  24. ncbi request reprint Open surgical management of renal cell carcinoma in the era of minimally invasive kidney surgery
    Dhiren S Dave
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095 1738, USA
    BJU Int 96:1268-74. 2005
  25. ncbi request reprint Role of molecular markers in the diagnosis and therapy of renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, California 90095 1738, USA
    Urology 66:1-9. 2005
    ..This article reviews the important molecular markers in RCC to date and discusses their role in the diagnosis, prognostication, and therapy of patients with RCC...
  26. ncbi request reprint Predicting response to interleukin-2 therapy among patients with renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    J Immunother 28:427-9. 2005
  27. ncbi request reprint Adjuvant therapy of renal cell carcinoma: patient selection and therapeutic options
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    BJU Int 96:483-8. 2005
  28. ncbi request reprint Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Cancer 109:2257-67. 2007
    ..The goal of the study was to evaluate the potential and limitations of targeting the mTOR pathway in renal cell carcinoma (RCC)...
  29. doi request reprint Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies
    Brian Shuch
    David Geffen School of Medicine, University of California Los Angeles UCLA, Los Angeles, CA 90095 1738, USA
    BJU Int 101:25-30. 2008
  30. doi request reprint Carbonic anhydrase IX: role in diagnosis prognosis and cancer therapy. Introduction
    Arie S Belldegrun
    BJU Int 101:1. 2008
  31. doi request reprint Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm
    Brian Shuch
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    BJU Int 102:692-6. 2008
    ....
  32. ncbi request reprint Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Clin Cancer Res 13:7388-93. 2007
    ..Here, we evaluated the significance of HIF-1 alpha in renal cell carcinoma (RCC)...
  33. pmc Proteomic identification of interleukin-2 therapy response in metastatic renal cell cancer
    Jon Jones
    Beth Israel Deaconess Medical Center Genomics Center and Dana Farber Harvard Cancer Center Cancer Proteomics Core, Boston, Massachusetts, USA
    J Urol 179:730-6. 2008
    ....
  34. ncbi request reprint In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist
    Alberto Breda
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095, USA
    J Urol 179:333-7. 2008
    ..We compared the lesion geometry of 3, 17 gauge cryoneedles to determine the most effective distance and configuration of the cryoneedles in an in vivo porcine kidney model...
  35. ncbi request reprint The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 179:61-6. 2008
    ..To evaluate its role in the biology of clear cell renal cell carcinoma we performed a tissue microarray based study...
  36. ncbi request reprint Cytoreductive nephron-sparing surgery does not appear to undermine disease-specific survival in patients with metastatic renal cell carcinoma
    Georg C Hutterer
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    Cancer 110:2428-33. 2007
    ..The disease-specific survival of patients with MRCC was compared according to the type of surgery, NSS (N=45) versus radical nephrectomy (RN) (N=732), in unmatched and matched analyses...
  37. ncbi request reprint A novel resectoscope for transurethral resection of bladder tumors and the prostate
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, 10833 Le Conte Ave, Room B7 298A CHS, Los Angeles, California 90025 1738, USA
    J Urol 178:2331-6; discussion 2336. 2007
    ..We performed a multicenter pilot and feasibility study of a novel working element for resectoscopes designed to improve the efficacy and safety of transurethral endoscopic surgery...
  38. ncbi request reprint Unclassified renal cell carcinoma: an analysis of 85 cases
    Pierre I Karakiewicz
    Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Quebec, Canada
    BJU Int 100:802-8. 2007
    ..To compare cancer-specific mortality in patients with unclassified renal cell carcinoma (URCC) vs clear cell RCC (CRCC) after nephrectomy, as URCC is a rare but very aggressive histological subtype...
  39. ncbi request reprint Prognostic factors for renal cell carcinoma with tumor thrombus extension
    Tobias Klatte
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90095 1738, USA
    J Urol 178:1189-95; discussion 1195. 2007
    ..We identified prognostic factors for renal cell carcinoma with tumor thrombus extension and assessed whether the current T3 classification could be improved...
  40. ncbi request reprint Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience
    Tobias Klatte
    Department of Urology, University of California, Los Angeles, Los Angeles, California 90095 1738, USA, and Centre Hospitalier Universitaire Pontchaillou, Rennes, France
    J Urol 178:35-40; discussion 40. 2007
    ..We examined the current pT2 tumor classification of renal cell carcinoma and determined whether a tumor size cutoff exists that would improve prognostic accuracy...
  41. ncbi request reprint Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy
    Karen L Reckamp
    Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA, USA
    J Immunother 30:417-24. 2007
    ..The CXCR3/CXCR3 ligand biologic axis and angiogenic ratio may be important biomarkers in clear cell RCC patients who are undergoing high dose IL-2 therapy...
  42. ncbi request reprint The role of molecular markers in the staging of renal cell carcinoma
    John T Leppert
    Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1738, USA
    BJU Int 99:1208-11. 2007
  43. ncbi request reprint Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials
    John S Lam
    University of California Los Angeles Kidney Cancer Program, Division of Urologic Oncology, Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Le Conte Avenue, Los Angeles, CA, USA
    Clin Cancer Res 13:703s-708s. 2007
    ..This article reviews the protein expression profiles in RCC and their association with pathobiology, prognosis, and response to treatment as well as their role in serving as potential molecular targets for therapy of RCC...
  44. ncbi request reprint Staging of renal cell carcinoma: current concepts
    Oleg Shvarts
    Division of Urologic Oncology, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    BJU Int 95:8-13. 2005
  45. ncbi request reprint A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma
    Barbara J Gitlitz
    Department of Medicine, Division of Hematology Oncology, David Geffen School of Medicine at University of California, Los Angeles, 10945 Le Conte Avenue, Suite 2333, Los Angeles, CA 90095, USA
    J Immunother 26:412-9. 2003
    ..Further clinical studies are needed to identify the most potent treatment regimen that can consistently mediate an antitumor immune response in vivo...
  46. ncbi request reprint Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California 90095 1738, USA
    Cancer 97:2995-3002. 2003
    ..The current study was performed to determine the impact of the presence of retroperitoneal lymphadenopathy on the survival and response to immunotherapy of patients with metastatic renal cell carcinoma (RCC)...
  47. ncbi request reprint Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection
    Allan J Pantuck
    Department of Urology, University of California School of Medicine, Los Angeles, California, USA
    J Urol 169:2076-83. 2003
    ..We better defined the benefits and morbidity of lymph node dissection in patients with localized renal cell carcinoma using the experience of patients treated at our institution...
  48. ncbi request reprint Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene
    Jose M Hernandez
    Department of Urology, University of California, Los Angeles 90095, USA
    Clin Cancer Res 9:1906-16. 2003
    ....
  49. ncbi request reprint Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system
    Stephen J Freedland
    Department of Urology, UCLA, Los Angeles, California 90095 1738, USA
    Prostate 55:299-307. 2003
    ..To study gene expression during prostate cancer progression and to identify molecular targets for therapy, a pure clonal tumor system was generated...
  50. ncbi request reprint Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer
    Stephen J Freedland
    Department of Urology, UCLA School of Medicine, Los Angeles, CA 90095 1738, USA
    Prostate 55:71-80. 2003
    ....
  51. ncbi request reprint Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
    Ken ryu Han
    Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Urology 61:314-9. 2003
    ..The most common sites of metastatic renal cell carcinoma (mRCC) are the lung and bone...
  52. ncbi request reprint Immune gene therapy for kidney cancer: the search for a magic trigger
    Hyung L Kim
    Department of Urology, University of California at Los Angeles, 10833 Le Conte Avenue, CHS 66 118, Los Angeles, CA 90095 1738, USA
    Mol Ther 7:153-4. 2003
  53. ncbi request reprint Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy
    Amnon Zisman
    Kimmel Cancer Center, Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, USA
    J Urol 169:909-16. 2003
    ..We outline the biology, prognosis and role of immunotherapy for renal cell carcinoma with gross venous tumor thrombus...
  54. ncbi request reprint Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
    Matthew H T Bui
    Department of Urology, University of California, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 9:802-11. 2003
    ..To date, there are no molecular markers which can reliably predict RCC outcome. We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is associated with progression and survival...
  55. ncbi request reprint Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease
    Frank Berger
    The Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology University of California School of Medicine, 700 Westwood Blvd, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 29:1225-36. 2002
    ..Morphological imaging with microCAT is useful to display correlative changes in anatomy. Detailed in vivo studies of the murine skeleton in various small animal models of bone diseases should now be possible...
  56. ncbi request reprint Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype
    Amnon Zisman
    Department of Biostatistics, University of California Los Angeles School of Medicine, Los Angeles, CA, USA
    J Urol 168:950-5. 2002
    ..We characterized the histopathological features and clinical behavior of unclassified renal cell carcinoma and compared the prognostic outcome in patients with unclassified and conventional (clear cell) renal cell carcinoma...
  57. ncbi request reprint Minimally invasive ablative approaches in the treatment of renal cell carcinoma
    Nicolette Janzen
    UCLA Department of Urology, 10833 Le Conte Ave, CHS 66 118, Los Angeles, CA 90035, USA
    Curr Urol Rep 3:13-20. 2002
    ..More data are needed to evaluate the efficacy of RFA. Currently, preclinical results with HIFU do not justify its use for treating RCC in humans...
  58. ncbi request reprint A randomized phase III trial of high dose interleukin-2 versus subcutaneous interleukin-2/interferon
    Ken ryu Han
    Curr Urol Rep 3:11-2. 2002
  59. ncbi request reprint Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 9:4641-52. 2003
    ....
  60. ncbi request reprint Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population
    Ken ryu Han
    Department of Urology, School of Medicine, University of California Los Angeles, 90095 1738, USA
    J Urol 170:2221-4. 2003
    ..In this study a previously published clinical outcome algorithm based on 1997 T stage, Fuhrman grade and performance score is validated using an international database...
  61. ncbi request reprint Basic biology and clinical behavior of renal cell carcinoma
    Ken ryu Han
    Department of Urology, University of California School of Medicine, 10833 Le Conte Avenue, Room 66 118 CHS, Los Angeles, CA 90095 1738, USA
    Cancer Treat Res 116:69-89. 2003
  62. ncbi request reprint The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model
    Nicolette K Janzen
    Department of Urology, University of California Los Angeles School of Medicine, 90095, USA
    J Urol 173:1368-74. 2005
    ..Indications and limitations of the technologies are still evolving. In a porcine model we evaluated the safety and efficacy of cryotherapy and radio frequency ablation (RFA) of cortical and deep renal tissue...
  63. ncbi request reprint G250: a carbonic anhydrase IX monoclonal antibody
    John S Lam
    Department of Medicine, David Geffen School of Medicine at UCLA, 2333 Peter Ueberroth Building, 10945 Le Conte Avenue, Los Angeles, CA 90095, USA
    Curr Oncol Rep 7:109-15. 2005
    ..These studies formed the basis of numerous clinical trials aimed at mAb-guided therapy in patients with metastatic RCC...
  64. ncbi request reprint Surveillance following radical or partial nephrectomy for renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, 66 118 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Curr Urol Rep 6:7-18. 2005
    ..Therefore, the timely identification of recurrences following surgical extirpation is imperative in the treatment of patients...
  65. ncbi request reprint Advances in immune-based therapies of renal cell carcinoma
    John S Lam
    Department of Urology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA 90095, USA
    Expert Rev Anticancer Ther 4:1081-96. 2004
    ..Such strategies are currently being tested in clinical trials...
  66. ncbi request reprint Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker
    Gang Zeng
    Department of Urology and Jonsson Comprehensive Cancer Center, 66 118 Center for Health Sciences, David Geffen School of Medicine at UCLA, Box 951738, Los Angeles, CA 90095, USA
    Int J Cancer 114:268-73. 2005
    ..This simple and straightforward approach may allow the investigation of the clinical significance of spontaneous Ab responses against multiple TAA and their correlation with the clinical course of malignant diseases in the future...
  67. ncbi request reprint Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma
    Tao Shi
    Department of Human Genetics, University of California, Los Angeles, CA 90095 7088, USA
    Mod Pathol 18:547-57. 2005
    ....
  68. ncbi request reprint Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines
    Alvin Y Liu
    Department of Urology, University of Washington, Seattle, 98195, USA
    Prostate 60:98-108. 2004
    ..Unlike LNCaP, the other cell lines show features of progressed disease such as metastatic capability and hormone independence. Analyses were done to determine if C4-2 or CL1 cells were selected from pre-existent subpopulations in LNCaP...
  69. ncbi request reprint Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma
    Ken ryu Han
    Department of Urology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095, USA
    Urology 63:841-6; discussion 846-7. 2004
    ..Increasing numbers of patients requiring renal surgery are presenting with substantial comorbidities, such as diabetes mellitus, chronic obstructive pulmonary disease, and cardiovascular disease...
  70. ncbi request reprint Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma
    Matthew H T Bui
    Departments of Urology, University of California Los Angeles, California 90095 1738, USA
    J Urol 171:2461-6. 2004
    ..The natural history of renal cell carcinoma (RCC) is complex and not entirely explained by conventional prognostic factors. In this study we evaluated the prognostic value of carbonic anhydrase IX (CAIX) and Ki67 to predict survival in RCC...
  71. ncbi request reprint Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma
    David B Seligson
    Department of Pathology and Laboratory Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, California 90095, USA
    Clin Cancer Res 10:2659-69. 2004
    ....
  72. ncbi request reprint Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer
    Allan J Pantuck
    Department of Urology, David Geffen School of Medicine at University of California, Los Angeles 90095, USA
    J Immunother 27:240-53. 2004
    ..These results suggest that VV/MUC-1/IL-2 gene therapy with a maximum tolerated dose of 5 x 10(7) pfu is safe and well tolerated...
  73. ncbi request reprint Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9
    Hideki Mukouyama
    Departments of Urology and Medicine, University of California Los Angeles, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 10:1421-9. 2004
    ..The ability to consistently generate a T-cell response is an important step toward the development of a CA9-specific RCC vaccine...
  74. ncbi request reprint Kidney cancer management in 2004: an update for the practicing general urologist
    John S Lam
    Department of Urology, David Geffen School of Medicine at UCLA 66 128 CHS, Box 951738, Los Angeles, CA 90095 1738, USA
    Curr Urol Rep 5:1-3. 2004
  75. ncbi request reprint Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease
    Nicolette K Janzen
    Department of Urology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, CHS 66 118, Los Angeles, CA 90095 1738, USA
    Urol Clin North Am 30:843-52. 2003
    ..Factors including patient comorbidities and patient willingness to pursue aggressive management in the event of recurrence may alter the follow-up for each individual...
  76. ncbi request reprint Mathematical model to predict individual survival for patients with renal cell carcinoma
    Amnon Zisman
    Division of Urologic Oncology, Department of Urology, University of California School of Medicine, Los Angeles, CA 90095 1738, USA
    J Clin Oncol 20:1368-74. 2002
    ..To develop a multivariate model and mathematical formula capable of calculating personalized survival for renal cell carcinoma (RCC) patients with clinically available variables...